Marqibo Interactions
There are 470 drugs known to interact with Marqibo (vincristine liposome), along with 6 disease interactions. Of the total drug interactions, 79 are major, 373 are moderate, and 18 are minor.
- View all 470 medications that may interact with Marqibo
- View Marqibo disease interactions (6)
Most frequently checked interactions
View interaction reports for Marqibo (vincristine liposome) and the medicines listed below.
- Adriamycin RDF (doxorubicin)
- Advate (antihemophilic factor)
- Adzenys XR-ODT (amphetamine)
- Alimta (pemetrexed)
- Alphanate (antihemophilic factor/von willebrand factor)
- amlodipine / hydrochlorothiazide / olmesartan
- Bactrim DS (sulfamethoxazole / trimethoprim)
- Baraclude (entecavir)
- Capastat (capreomycin)
- Celestone Soluspan (betamethasone)
- Cipro I.V. (ciprofloxacin)
- Copiktra (duvelisib)
- Cotempla XR-ODT (methylphenidate)
- Crixivan (indinavir)
- Cytoxan (cyclophosphamide)
- Decadron (dexamethasone)
- Duopa (carbidopa / levodopa)
- Enbrel (etanercept)
- Epivir-HBV (lamivudine)
- Etopophos (etoposide)
- Feiba (anti-inhibitor coagulant complex)
- Gamifant (emapalumab)
- Gammagard S/D (immune globulin intravenous)
- gemfibrozil
- glimepiride / rosiglitazone
- Hemofil-M (antihemophilic factor)
- HepaGam B (hepatitis b immune globulin)
- Humate-P (antihemophilic factor/von willebrand factor)
- Humatin (paromomycin)
- Humira (adalimumab)
Marqibo disease interactions
There are 6 disease interactions with Marqibo (vincristine liposome) which include:
- pulmonary dysfunction
- neurologic dysfunction
- constipation
- hepatic dysfunction
- infections
- myelosuppression
Report options
More about Marqibo (vincristine liposome)
- Marqibo consumer information
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: mitotic inhibitors
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Blinatumomab
Blinatumomab (Blincyto) is an injectable immunotherapy treatment that may be used to treat B-cell ...
Mercaptopurine
Mercaptopurine systemic is used for acute lymphoblastic leukemia, autoimmune hepatitis, crohn's ...
Dasatinib
Dasatinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) ...
Doxorubicin
Doxorubicin systemic is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.